The transformative efficacy of EV-Pembro has ushered in a new, aggressive treatment philosophy for both muscle-invasive and metastatic bladder cancer. The approach is to administer the combination upfront to gain rapid disease control, and only then make subsequent decisions about surgery, radiation, or further therapy.

In early-stage bladder cancer, where the goal is a cure, the argument to "save a therapy for later" is flawed. The primary objective should be to use the most effective treatment upfront. Withholding it doesn't make it more effective upon relapse; it just gives the cancer an opportunity to progress.

High relapse rates (~70%) in surgery-alone arms of recent trials suggest most patients with muscle-invasive bladder cancer (MIBC) already have micrometastatic disease. This reframes the disease, prioritizing early systemic therapy over immediate surgery to achieve control and potential cure.

New bladder-sparing trials mandate nine cycles of EV-Pembro to replicate the conditions of successful surgical trials. This conservative approach ignores that patient response is front-loaded while toxicity is back-loaded, likely overtreating many patients to ensure comparable efficacy.

Giving EV Pembro perioperatively for muscle-invasive bladder cancer provides the best chance for a cure. Waiting to use it in the first-line metastatic setting is a major gamble, as many patients relapse and may not get a second chance at effective therapy. The consensus is to use the best treatment upfront.

Expert consensus shows a major paradigm shift: perioperative systemic therapy (like EV-Pembro, scoring 2.9) is the undisputed standard for muscle-invasive bladder cancer. Approaches starting with cystectomy alone now score below 1.8, formally branding them as inferior options.

A key lesson in bladder cancer is that patient attrition is rapid between lines of therapy; many who relapse from localized disease never receive effective later-line treatments. This reality provides a strong rationale for moving the most effective therapies, like EV-pembrolizumab, to earlier settings to maximize the number of patients who can benefit.

With pathologic complete response rates approaching 67% in patients completing neoadjuvant EV-Pembro, a majority of cystectomies are now removing cancer-free bladders. This creates an ethical and clinical imperative to rapidly launch prospective trials to validate bladder preservation strategies and avoid overtreatment.

A contrarian viewpoint, dubbed the "Gillison Paradox," argues that patients achieving a complete response are precisely the ones who should receive more therapy. Their strong response indicates drug sensitivity, making it logical to continue treatment to eradicate any remaining micrometastatic disease, rather than de-escalating.